1. Protein Tyrosine Kinase/RTK Apoptosis
  2. FGFR Apoptosis
  3. Formononetin

Formononetin  (Synonyms: Biochanin B; Flavosil; Formononetol)

Cat. No.: HY-N0183 Purity: 98.99%
SDS COA Handling Instructions

Formononetin is a potent FGFR2 inhibitor with an IC50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth.

For research use only. We do not sell to patients.

Formononetin Chemical Structure

Formononetin Chemical Structure

CAS No. : 485-72-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 61 In-stock
Solution
10 mM * 1 mL in DMSO USD 61 In-stock
Solid
5 mg USD 35 In-stock
10 mg USD 55 In-stock
50 mg USD 72 In-stock
100 mg USD 99 In-stock
200 mg USD 165 In-stock
500 mg USD 231 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 14 publication(s) in Google Scholar

Other Forms of Formononetin:

Top Publications Citing Use of Products

View All FGFR Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Formononetin is a potent FGFR2 inhibitor with an IC50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth[1].

IC50 & Target[1]

FGFR2

4.31 μM (IC50)

Cellular Effect
Cell Line Type Value Description References
A549 IC50
> 100 μM
Compound: 13
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
[PMID: 18440233]
A549 ED50
2.87 μg/mL
Compound: 11
Cytotoxicity against human A549 cells after 7 days
Cytotoxicity against human A549 cells after 7 days
[PMID: 8201311]
B16-BL6 IC50
> 100 μM
Compound: 13
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
[PMID: 18440233]
BV-2 IC50
> 100 μM
Compound: 19
Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 25466192]
BV-2 IC50
13.19 μM
Compound: 2
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
[PMID: 28911817]
DU-145 IC50
> 100 μM
Compound: Formononetin
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
[PMID: 22633834]
ECa-109 cell line IC50
> 100 μM
Compound: 1
Cytotoxicity against human EC109 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human EC109 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
[PMID: 28038329]
HCT-116 IC50
60.97 μM
Compound: Formononetin
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
[PMID: 22633834]
HeLa IC50
> 100 μM
Compound: 13
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
[PMID: 18440233]
HeLa IC50
8.51 μM
Compound: Formononetin
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
[PMID: 22633834]
HepG2 IC50
60.5 μM
Compound: 15
Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 24974349]
HT-1080 IC50
> 100 μM
Compound: 13
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
[PMID: 18440233]
HT-29 ED50
6.43 μg/mL
Compound: 11
Cytotoxicity against human HT-29 cells after 7 days
Cytotoxicity against human HT-29 cells after 7 days
[PMID: 8201311]
Lewis lung carcinoma cell line IC50
> 100 μM
Compound: 13
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
[PMID: 18440233]
MCF7 ED50
1.96 μg/mL
Compound: 11
Cytotoxicity against human MCF7 cells after 7 days
Cytotoxicity against human MCF7 cells after 7 days
[PMID: 8201311]
MDCK CC50
123 μM
Compound: 3
Cytotoxicity against MDCK cells after 72 hrs
Cytotoxicity against MDCK cells after 72 hrs
[PMID: 24313801]
MDCK IC50
38.2 μM
Compound: 3
Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
[PMID: 24313801]
MDCK IC50
42.6 μM
Compound: 3
Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
[PMID: 24313801]
MGC-803 IC50
> 100 μM
Compound: 1
Cytotoxicity against human MGC803 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human MGC803 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
[PMID: 28038329]
N9 IC50
> 100 μM
Compound: 4
Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 28073678]
PC-3 IC50
57.01 μM
Compound: 1
Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
[PMID: 28038329]
RAW264.7 IC50
56.1 μM
Compound: 6
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 23743282]
SGC-7901 IC50
2.17 μM
Compound: Formononetin
Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
[PMID: 22633834]
SH-SY5Y IC50
> 100 μM
Compound: Formononetin
Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
[PMID: 22633834]
U-937 IC50
44 μM
Compound: 6, formononetin
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
[PMID: 17158054]
U-937 IC50
45 μM
Compound: 6, formononetin
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
[PMID: 17158054]
U-937 IC50
50 μM
Compound: 6, formononetin
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
[PMID: 17158054]
In Vitro

Formononetin is one of the major isoflavonoid constituents isolated from Astragalus membranaceus and has been demonstrated diverse pharmacological benefits. Formononetin possesses anti-angiogenic activity in human colon cancer cells. Formononetin also promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells[1].
Formononetin (25 to 150 μM) markedly decreases the proliferation of endothelial cells stimulated by FGF2[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HUVECs
Concentration: 0, 10, 25, 50, 75, 100, and 150 μM
Incubation Time:
Result: Significantly decreased the proliferation of HUVECs stimulated by FGF2 in a dose-dependent manner, while had little inhibitory effects on HUVECs that were not stimulated by FGF2.
In Vivo

Formononetin dramatically suppresses tumor volumes and the Formononetin-treated group tumor weight are significantly inhibited compared with the vehicle group . Formononetin treatment is well tolerated, and there is no significant difference in weight between vehicle group and formononetin treated groups[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice bearing MDA-MB-231 xenografts[1]
Dosage: 100 mg/kg
Administration: Treated daily by intragastric administration for 25 days
Result: Inhibited breast cancer growth and angiogenesis in vivo.
Molecular Weight

268.26

Formula

C16H12O4

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C1C(C2=CC=C(OC)C=C2)=COC3=CC(O)=CC=C13

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
Solvent & Solubility
In Vitro: 

DMSO : ≥ 35 mg/mL (130.47 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.7277 mL 18.6386 mL 37.2773 mL
5 mM 0.7455 mL 3.7277 mL 7.4555 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (9.32 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (9.32 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 5 mg/mL (18.64 mM); Suspended solution; Need ultrasonic

  • Protocol 2

    Add each solvent one by one:  0.5% CMC-Na/saline water

    Solubility: 25 mg/mL (93.19 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 98.99%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.7277 mL 18.6386 mL 37.2773 mL 93.1932 mL
5 mM 0.7455 mL 3.7277 mL 7.4555 mL 18.6386 mL
10 mM 0.3728 mL 1.8639 mL 3.7277 mL 9.3193 mL
15 mM 0.2485 mL 1.2426 mL 2.4852 mL 6.2129 mL
20 mM 0.1864 mL 0.9319 mL 1.8639 mL 4.6597 mL
25 mM 0.1491 mL 0.7455 mL 1.4911 mL 3.7277 mL
30 mM 0.1243 mL 0.6213 mL 1.2426 mL 3.1064 mL
40 mM 0.0932 mL 0.4660 mL 0.9319 mL 2.3298 mL
50 mM 0.0746 mL 0.3728 mL 0.7455 mL 1.8639 mL
60 mM 0.0621 mL 0.3106 mL 0.6213 mL 1.5532 mL
80 mM 0.0466 mL 0.2330 mL 0.4660 mL 1.1649 mL
100 mM 0.0373 mL 0.1864 mL 0.3728 mL 0.9319 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Formononetin
Cat. No.:
HY-N0183
Quantity:
MCE Japan Authorized Agent: